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Summary 
Because of its ability to efficiently inhibit in vitro cytokine production by activated macrophages, 
we hypothesized that interleukin (IL) 10 might be of particular interest in preventing endotoxin- 
induced toxicity We therefore examined the effects of Ibl0 administration before lipopolysaccharide 
(LPS) challenge in mice. A  marked reduction in the amounts of LPS-induced tumor necrosis 
factor (TNF) release  in the circulation  was observed after IL-10 pretreatment  at doses as low 
as 10 U. Ibl0 also efficiently prevented the hypothermia generated by the injection of 100 #g 
LPS.  Finally,  pretreatment  with  a single injection of 1,000 U  Ibl0 completely prevented the 
mortality  consecutive to  the challenge  with  500 #g LPS,  a dose that  was lethal  in  50%  of 
the control mice. We conclude that  Ibl0 inhibits in vivo TNF secretion and protects against 
the lethality  of endotoxin  in a murine  model of septic shock. 
E 
ndotoxin (LPS) from gram-negative bacteria is a major 
causative agent in the pathogenesis of septic shock (1). 
A  shock-like state can indeed be induced experimentally by 
a single injection of LPS into animals.  These toxic effects of 
LPS are mostly related to macrophage activation leading to 
the release of multiple inflammatory mediators. Among these 
mediators,  TNF appears to play a crucial role, as indicated 
by the prevention of LPS toxicity by the administration  of 
neutralizing  anti-TNF  antibodies  (2-5). 
Ibl0 is a recently described cytokine that efficiently blocks 
the in vitro production of TNF as well as of other cytokines 
by LPS-activated monocytes/maerophages (6-8). Ibl0 might 
therefore be an efficient agent to downregulate LPS toxicity 
in vivo. To test this hypothesis,  we analyzed the effects of 
IL-10 administration before LPS challenge in mice, focusing 
on the systemic release of TNF, hypothermia,  and lethality. 
Materials and Methods 
Animals.  10-15-wk-old BALB/c mice were purchased from the 
KUL Proef Dieren  Centrum  (Leuven, Belgium). 
Reagents.  LPS from Esche6chia coli (serotype O55:B5) was pur- 
chased from Sigma Chemical Co. (St. Louis, MO). The JES5-2A5 
mAb, a neutralizing  rat anti-mouse Ibl0 IgG1 mAb, was kindly 
given by Tim Mosmann (Department  of Immunology,  University 
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of Alberta, Edmonton, Canada) (9). The LO-DNP mAb, a rat IgG1 
antibody used as control,  was a kind gift  from H. Bazin  (Ex- 
perimental Immunology Unit, Universit6 Catholique de Louvain, 
Brussels, Belgium). 
Mouse Recombinant 1I.,10: Cloning and Expression.  Specific  oli- 
gonucleotides  for the murine  IL-IO cDNA were synthesized ac- 
cording to its sequence (10), Restriction  sites were added to their 
5' end for subcloning: HinclI/SaclI for the sense primer 5'-CTC- 
CATCATGCCTGGCTCA-Y  (nucleotide 69-87) and SmaI/XhoI 
for the antisense primer 5'-TACACACTGCAGGTGTTTTAGC-Y 
(nucleotide 608-629). Total KNA was prepared from the spleen 
of mice injected with the hamster anti-CD3  mAb 145-2Cll as a 
nonspecific stimulator  of cytokine transcription  (11). 1 #g KNA 
was reverse transcribed using the antisense oligonudeotide (1/xg) 
as primer and 200 U Moloney-murine leukemia virus (Mo-MuLV) 
reverse transcriptase (KT) (Promega Corp., Madison, WI) in KT 
buffer (50 mM KC1, 20 mM "Iris HC1, pH 8.3, 2.5 mM MgC12, 
0.1 mg/ml acetylated BSA, dNTPs 2.5 mM each, KNasin  20 U 
[Promega Corp.]) in a final volume of 20 #1. To this were added 
2.5 U  Taq DNA polymerase, and  1 #g of each sense/antisense 
primer, in the same buffer, and in a total volume of 100 #1. A PCK 
was performed using a DNA thermal cycler (Perkin-Elmer Cetus, 
Norwalk, CT) for 35 cycles: 1 min denaturation  at 94~  2 rain 
annealing at 55~  and 3 min extension at 72~  A band with 
the  560-bp predicted  size was obtained.  The  specificity of the 
amplified cDNA was validated by its restriction pattern. Sequencing 
was also performed following the dideoxynucleotide chain termi- 
nation method (12). Nucleotides 322, 465-468, 522, and 523 were 
different from those published (10), but the amino acids remained 
unchanged.  The SaclI-XhoI restriction  fragment,  containing  the 
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virus-derived retroviral vector pCO6-HX in place of the coding 
sequence of p21 ras (see Fig.  1) (13). In this construction,  called 
pTG1H-mlL10, the IL-10 cDNA is the only functional gene.  A 
similar vector, with no inserted II.-10 gene, was used as negative 
(mock) control. To derive individual colonies of cells expressing 
high  levels of Ibl0,  pTG1H-mlL10 was cotransfected with  the 
plasmid pSV2-neo, which contains the neomycin resistance gene 
used as a selectable marker. Transfection was performed in the CHO- 
K1 (Chinese hamster ovarian K1) cell line using a modified cal- 
cium phosphate method as described, except that no carrier DNA 
was present (14). Selection for transfectants was initiated by adding 
400/~g/ml G418 (Geneticin; Gibco, Paisley, Scotland).  10 d later, 
individual resistant colonies were isolated and tested for IL-10 ex- 
pression using a specific enzyme-linked immunosorbent assay (Phar- 
mingen, San Diego). IL-10 concentrations were determined by ref- 
erence to a standard curve of recombinant IL-10 expressed in COS 
cell supernatant (470 U/ml) (Pharmingen). The supernatant col- 
lected after 24 h culture of a colony with high II.-10 level (200 U/ml) 
was concentrated to 5,000 U IL-10/ml on an ultrafiltration mem- 
brane (Amicon Corp., Danvers, MA).  Control (mock) superna- 
rant from CHO-K1 cells transfected with the control plasmid and 
with pSV2-neo has been selected, collected,  and concentrated simi- 
larly. The endotoxin content of the injected preparations was below 
1 ng/ml. 
Determination  of Serum  TNF Levels.  Blood samples were ob- 
tained from individual mice by retroorbital puncture. Serum levels 
of TNF were estimated by a cytotoxicity assay on actinomycin- 
D-treated WEHI-164 clone 13 cells as previously described (15). 
Results were expressed in pg/ml in reference to the cytotoxic ac- 
tivity of a standardized  (National Biological Standards Board, Hert- 
fordshire,  UK) preparation of recombinant murine TNF expressed 
in Escherichia coli (16). This preparation had a specific biological 
activity of 2.25  ￿  10  s IU/mg,  with  1  IU representing  about 
4 pg routine TNF. We found that IL-10 was not interfering with 
this bioassay (data not shown). 
Experimental Protocol.  Mice were injected intravenously with 
100 #g of LPS 30 min after an intraperitoneal administration  of 
either CHO-IL10 or mock supernatants. Serum TNF levels were 
determined 1.5, 3, and 6 h after LPS challenge, whereas rectal tem- 
perature was measured at regular intervals with a digital thermom- 
eter.  In another series of experiments, we evaluated the effects of 
IL-10 on the lethality induced by a single dose of 500 #g LPS. 
Statistics.  TNF levels and temperatures were compared using 
the Mann-Whitney U test. Lethality data were analyzed with the 
Fisher's exact  test. 
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Figure  1.  Construction of the routine IL-10  retroviral vector. Plasmid 
pTGIH-mlL10 was derived from the Harvey murine sarcoma virus (Ha- 
MuSV) cloned in pBR322 (pCO6-HX) (13). The entire coding region 
of v-ras  H (SaclI-Xhol) was removed and replaced by the 560-bp fragment 
coding for the routine IL-10  cDNA. (Solid  lines) Ha-MuSV sequences; (broken 
lines) pBR322. Restriction eodonucleases sites: (H) HindlII; (S) SaclI; (X) 
XhoI; (B) BamHI. (B/ack  box) Coding sequences of IL-10; (open box)  coding 
sequences of v-rasH; and (crosshatched boxes) Ha-MuSV LTRs. 
Table  1.  Effects  of Various Doses of lL-lO  on  the systemic 
release of TNF Induced  by LPS 
TNF  serum levels 
Pretreatment  Challenge  1.5  h  3  h 
pg/ml 
Medium  -  <10  <10 
Medium  LPS  5268  +_  1118  <10 
Mock  LPS  5270  _+  1283  <10 
IL-10 (10  U)  LPS  1216  _+  469*  ND 
IL-10 (100  U)  LPS  1846  _+  1295'  ND 
IL-10 (1,000  U)  LPS  416  _+  70  s  <10 
IL-10 (1,000  U)  -  <10  ND 
BALB/c mice (n =  5 in each group) were injected intraperitoneally with 
the indicated doses of IL-IO, 30 min before an intravenous injection of 
100/zg LPS. As control, mice were pretreated with either the medium 
used for culturing CHO-K1 cells, or the mock supernatant. Serum levels 
of biologically active TNF (mean + SEM) were determined 1.5 and 3 h 
after LPS challenge. 
* p <0.01, t p <0.05, and S  p <0.005, as compared with mice pretreated 
either  with  control  medium  or  with  mock  supernatant  before LPS 
challenge. 
Results and Discussion 
To assess the in vivo effects of ID10 administration on LPS- 
induced TNF release, three different doses of IL-10 (10, 100, 
or 1,000 U) were given intraperitoneally 30 min before the 
intravenous injection of 100 #g LPS. Since previous studies 
showed  that  TNF  levels peaked  1.5  h  after LPS chalhnge, 
blood samples were taken at that  time (17).  II:10 pretreat- 
ment resulted in a  significant  reduction  in the  amounts  of 
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Figure  2.  Time course of rectal temperature (mean _ SEM) in IIALt]/c 
mice (6-21 per group) injected with either medium alone (O); LPS (100 
~g i.v.) without pretreatment (0); LPS (100 #g i.v.) after pretreatment 
with 1,000 U II.~10  (V); or LPS (100 #g i.v.) after pretreatment with su- 
pernatant from mock-transfected CHO-K1 cells (V). 
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Lethality after injection of 500/~g LPS in three groups of 
BALB/c  mice:  (O)  mice with  no  pretreatment  (n  =  15); (~7) mice 
pretreated intraperitoneally with  1,000  U  I1.-10 (n  =  15); (V)  mice 
pretreated intraperitoneally with supernatant from mock-transfected CHO- 
K1 cells (n =  10). Two-tailedp value has been determined with the Fisher's 
exact test. 
TNF released in the circulation after LPS challenge, as shown 
in Table I representing one out of three experiments which 
gave similar results. This in vivo effect of II.-10 was already 
observed with doses as low as 10 U  (p <0.01  as compared 
with  LPS  after  pretreatment with control medium).  As 
1,000 U had a more pronounced and reproducible activity, 
this dose was chosen for further studies. The specificity of 
the effect of the I1-10 preparation was assessed  by pretreating 
mice with a supernatant from mock-transfected  CHO-K1 cells. 
As shown in Table 1, this control preparation  had no effect 
on TNF release. TNF serum levels returned to baseline values 
3 h after LPS challenge in all groups of mice, indicating that 
ILl0 did not merely delay the release of TNF (Table 1). 
As a first approach to evaluate in vivo the effect of I1.10 
on LPS-induced toxicity, we monitored rectal temperature 
for 24 h after challenge with 100/~g LPS. Indeed, as previ- 
ously reported by others, LPS caused a profound hypothermia 
which is probably related  to TNF  release (18). The data 
presented in Fig. 2 indicate that II.-10 pretreatment efficiently 
prevented LPS-induced hypothermia (p <0.0001 at 4 h, and 
p <0.005 at 6 h, as compared either with LPS alone or LPS 
after pretreatment with mock superuatant), whereas control 
superuatant  from mock-transfected  CHO-K1 cells had no 
significant effect. A substantial variation in the recovery from 
hypothermia was seen among the animals injected with 100 
/~g LPS, either given alone or after pretreatment with mock 
supernatant.  As an additional control of specificity for the 
effect observed after pretreatment with CHO-IL10 superna- 
tant, we added 1 mg of the neutralizing anti-mouse I1.10 
JES5-2A5  mAb or of a control rat IgG1 LO-DNP mAb to 
the II.-10 preparation.  The anti-I1.10 completely abrogated 
the protective effect of I1.-10 on hypothermia  whereas the con- 
trol rat mAb had no effect (data not shown). 
To evaluate the effect of I1.10 pretreatment on LPS-induced 
lethality, mice were challenged with 500/~g LPS, a dose which 
is lethal within 72 h in 50% of  the animals. All mice pretreated 
with  1,000 U  II,10  survived  the LPS injection,  whereas 
pretreatment with supernatant from mock-transfected CHO- 
K1 cells did not modify the LPS-induced lethality (Fig. 3). 
Taken together, these data indicate that pretreatment with 
I1-10 prevents the toxicity of LPS in a murine model of en- 
dotoxin shock. The beneficial effect of I1-10 could be due 
at least in part to the reduction of TNF release. Indeed, a 
similar level of protection against LPS-induced lethality has 
been obtained by the use of neutralizing anti-TNF antibodies 
(2-5). In vitro data suggest that I1-10 might also prevent the 
release of other monocyte/macrophage-derived  cytokines in- 
volved in the pathogenesis of septic shock, especially I1-1 (1, 
6,  19,  20). 
I1.-10 can therefore be added to the potential  immunoin- 
tervention strategies for the prevention and/or treatment of 
septic shock, which already include anti-TNF  mAb (2-5), 
I1.1 receptor antagonist  (21-23),  differentiation  factor/leu- 
kemia inhibitory factor (24), and G-CSF (25). Because of its 
deactivation effect on macrophages, I1-10 therapy might be 
of particular interest, possibly in combination with some of 
these other biological  agents. 
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